Diversified Funding MIDAS has secured $3.2M in funding and recently closed a $2M financing round, indicating investor confidence and potential for accelerated growth. This financial position can support scaling sales efforts, expanding product trials, and hiring regional sales personnel to drive adoption in more healthcare facilities.

Board and Leadership addition of Bryan Scheetz to the Board signals strategic governance focus on healthcare and enterprise solutions. Leverage board connections and credibility in discussions with health systems, distributors, and large multi-site accounts to open pilots and strategic partnerships.

Diversion Prevention Niche Product focus on preventing medication theft and abuse (diversion) positions MIDAS in a critical safety and compliance niche within hospitals and home care. Target patient safety officers, pharmacy directors, and compliance leaders with value propositions around reducing losses, improving accountability, and supporting regulatory requirements.

Growth Readiness Small to mid-sized team (11-50 employees) with a patent-pending portfolio suggests agility but also a need for scalable sales processes. Propose channel partnerships, interoperability demonstrations, and pilot programs with mid to large health systems to demonstrate ROI at scale.

Tech and Integration Existing tech stack and emphasis on traceability and accountability offer opportunities for integration with hospital information systems, medication management platforms, and caregiver workflows. Position as a compatible, low-friction add-on to existing tech ecosystems to accelerate procurement cycles.